PerkinElmer, Inc. (NYSE:PKI) insider Frank Anders Wilson sold 37,535 shares of PerkinElmer stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $70.14, for a total transaction of $2,632,704.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of PerkinElmer, Inc. (PKI) opened at $71.03 on Friday. The company has a current ratio of 2.59, a quick ratio of 2.09 and a debt-to-equity ratio of 0.44. PerkinElmer, Inc. has a 12-month low of $50.59 and a 12-month high of $74.11. The firm has a market cap of $7,727.89, a PE ratio of 25.22, a PEG ratio of 2.10 and a beta of 0.77.

The company also recently declared a quarterly dividend, which will be paid on Friday, February 9th. Investors of record on Friday, January 19th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.39%. The ex-dividend date of this dividend is Thursday, January 18th. PerkinElmer’s dividend payout ratio is currently 7.78%.

Hedge funds have recently made changes to their positions in the stock. Acrospire Investment Management LLC lifted its holdings in PerkinElmer by 185.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,000 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 1,300 shares during the last quarter. Waldron LP bought a new position in PerkinElmer during the 3rd quarter valued at about $200,000. Seaward Management Limited Partnership bought a new position in PerkinElmer during the 3rd quarter valued at about $202,000. Carret Asset Management LLC bought a new position in PerkinElmer during the 2nd quarter valued at about $210,000. Finally, Cipher Capital LP bought a new position in PerkinElmer during the 2nd quarter valued at about $230,000. 91.66% of the stock is owned by hedge funds and other institutional investors.

PKI has been the topic of several recent analyst reports. Cowen reiterated a “hold” rating and issued a $70.00 target price on shares of PerkinElmer in a report on Friday, September 1st. Citigroup reiterated a “buy” rating and issued a $80.00 target price (up previously from $74.00) on shares of PerkinElmer in a report on Tuesday, September 26th. Goldman Sachs Group restated a “neutral” rating and issued a $67.00 price target on shares of PerkinElmer in a research report on Tuesday, September 26th. Morgan Stanley restated an “overweight” rating and issued a $77.00 price target (down from $79.00) on shares of PerkinElmer in a research report on Friday, October 6th. Finally, Robert W. Baird restated a “buy” rating and issued a $72.00 price target on shares of PerkinElmer in a research report on Friday, October 20th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the company. PerkinElmer presently has an average rating of “Hold” and a consensus target price of $68.64.

WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/10/frank-anders-wilson-sells-37535-shares-of-perkinelmer-inc-pki-stock.html.

PerkinElmer Company Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Insider Buying and Selling by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Stock Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related stocks with our FREE daily email newsletter.